Hematologic profiles with bortezomib in relapsed MM

被引：0
|
作者：
Lonial, S.
Richardson, P. G.
Miguel, J. San
Sonneveld, P.
Schuster, M.
Blade, J.
Cavenagh, J.
Rajkumar, V.
Jakubowiak, A.
Esseltine, D.
Anderson, K. C.
Harousseau, J.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Hosp Univ Salamanca, Salamanca, Spain
[4] Univ Rotterdam Hosp, Rotterdam, Netherlands
[5] NY Presbyterian Hosp, New York, NY USA
[6] Univ Barcelona, Barcelona, Spain
[7] St Bartholomews Hosp, London, England
[8] Mayo Clin, Rochester, MN USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Millennium Pharmaceut Inc, Cambridge, MA USA
[11] Hop Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
MULTIPLE-MYELOMA; REFRACTORY MYELOMA; PHASE-2;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：159 / 160
页数：2
相关论文
共 50 条
  • [31] Update on the proteasome inhibitor bortezomib in hematologic malignancies
    Goy, A
    Gilles, F
    CLINICAL LYMPHOMA, 2004, 4 (04): : 230 - 237
  • [32] Bortezomib: A novel chemotherapeutic agent for hematologic malignancies
    Utecht, Kyle N.
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (13) : 1221 - 1231
  • [33] Phase 1 clinical trial of KOS-953 plus bortezomib (BZ) in relapsed refractory multiple myeloma (MM).
    Chanan-Khan, A.
    Richardson, P.
    Alsina, M.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Albitar, M.
    Hannah, A. L.
    Johnson, R. G.
    Anderson, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 137S - 137S
  • [34] LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES
    Dranitsaris, G.
    Kaura, S.
    HAEMATOLOGICA, 2012, 97 : 620 - 620
  • [35] Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
    Vogl, Dan T.
    Raje, Noopur
    Hari, Parameswaran
    Jones, Simon S.
    Supko, Jeffrey G.
    Leone, Gina
    Wheeler, Catherine
    Orlowski, Robert Z.
    Richardson, Paul G.
    Lonial, Sagar
    Tamang, David
    Jagannath, Sundar
    BLOOD, 2014, 124 (21)
  • [36] LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES
    Kaura, S.
    Dranitsaris, G.
    VALUE IN HEALTH, 2012, 15 (07) : A508 - A509
  • [37] Efficacy of bortezomib in elderly MM patients
    Schlag, R.
    Zeller, W.
    Dietzfelbinger, H.
    Pliskat, H.
    Angermund, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 166 - 166
  • [38] Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor
    Lu, Jin
    Fu, Weijun
    Li, Wei
    Hu, Jianda
    An, Gang
    Wang, Yafei
    Fu, Chengcheng
    Chen, Lijuan
    Jin, Jie
    Cen, Xinan
    Ge, Zheng
    Cai, Zhen
    Niu, Ting
    Spencer, Andrew
    Weisel, Katja
    Mateos, Maria-Victoria
    Nooka, Ajay
    Qi, Ming
    Sun, Steven
    Gai, Xue
    Liu, Weiping
    Yang, Xue
    Huang, Xiaojun
    BLOOD, 2020, 136
  • [39] The treatment of relapsed and refractory myeloma: Focus on bortezomib and bortezomib-based combinations
    Richardson, P.
    Schlossman, R.
    Ghobrial, I.
    Mitsiades, C.
    Hicleshima, T.
    Chauhan, D.
    Munshi, N.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 21 - 22
  • [40] Bortezomib in combination with dexamethasone for relapsed multiple myeloma
    Kropff, MH
    Bisping, G
    Wenning, D
    Volpert, S
    Tchinda, J
    Berdel, EW
    Kienast, J
    LEUKEMIA RESEARCH, 2005, 29 (05) : 587 - 590
12345